Janssen EMEA מקבלת אישור שיווק מותנה עבורRYBREVANT® ▼ (amivantamab), הטיפול הראשון שאושר עבור חולים עם סרטן ריאות מתקדם – מסוג תאים לא קטנים (NSCLC

Janssen EMEA מקבלת אישור שיווק מותנה עבורRYBREVANT^® ?(amivantamab), הטיפול הראשון שאושר עבור חולים עם סרטן ריאות מתקדם – מסוג תאים לא קטנים (NSCLC) עם 20 מוטציות EGFR Exon

חברת התרופות Janssen של ג'ונסון אנד ג'ונסון הודיע על אישור שיווק מותנה (CMA) של RYBREVANT^® ? (amivantamab) לטיפול בחולים מבוגרים עם NSCLC מתקדם עם הפעלת קולטן גורם גדילה אפידרמלי (EGFR) אקסון עם 20 מוטציות, לאחר כישלון של טיפול מבוסס תכשיר פלטיניום. Amivantamab הוא הטיפול המאושר הראשון באיחוד האירופי במיוחד למוטציות החדרת EGFRexon 20עבור NSCLC.

Janssen EMEA Receives Conditional Marketing Authorisation for RYBREVANT^® ? (amivantamab), the First Treatment Approved for Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations...

For EU Trade and Medical Media Only. Not to Be Distributed to UK and Benelux Based Media

Conditional Marketing Authorisation is based on results from the Phase 1 CHRYSALIS study evaluating amivantamab as a monotherapy in patients after previous treatment with platinum-based therapy^1,2,3

BEERSE, Belgium, 10 December 2021, (BUSINESS WIRE):

Janssen EMEA Receives Conditional Marketing Authorisation for RYBREVANT^® ? (amivantamab), the First Treatment Approved for Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations After Failure of Platinum-Based Therapy

The Janssen Pharmaceutical Companies of Johnson & Johnson announced Conditional Marketing Authorisation (CMA) of RYBREVANT^® ? (amivantamab) for the treatment of adult patients with advanced NSCLC with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations, after failure of platinum-based therapy.¹ Amivantamab is the first approved treatment in the European Union specifically targeting EGFR exon 20 insertion mutations for NSCLC.^1,2,4

"Patients with NSCLC harbouring EGFR exon 20 insertion mutations represent a specific population who have been underserved by current treatment options that are limited in both number and efficacy.⁵ The decision made by the European Commission represents an important milestone and recognises that amivantamab offers a new treatment specifically targeted for patients with this alteration," said Antonio Passaro, M.D., Ph.D, Medical Oncologist at the Division of Thoracic Oncology of the European Institute of Oncology in Milan, Italy.^†

The CMA is based on results from the Phase 1 CHRYSALIS study, a multicentre, open-label, clinical study evaluating amivantamab as a monotherapy in patients after previous treatment with platinum-based therapy, which demonstrated efficacy and a generally well-tolerated safety profile.^‡4,6 The investigator-assessed overall response rate was 37 percent (95 percent CI, 28% - 46%), with a median duration of response of 12.5 months (95 percent CI, 6.5 – 16.1) and 64 percent of patients having a duration of response greater than or equal to 6 months.⁴ These results were consistent with those reported by blinded independent central review assessment, which showed an overall response rate of 43 percent (34% – 53%), with a median duration of response of 10.8 months (95 percent CI, 6.9 – 15.0) and 55 percent of patients having a duration of response greater than or equal to 6 months.⁴

Analysis showed the median progression-free survival (time experienced without progression or death) was 8.3 months (95 percent CI, 6.5 – 10.9) and the median overall survival in patients treated with amivantamab was 22.8 months (95 percent CI, 14.6 – not reached).⁶

The most common adverse events (AEs) at all grades included rash (76 percent), infusion-related reactions (67 percent) and nail toxicity (47 percent), and these were predominantly Grade 1-2.⁴ Treatment-related discontinuations due to adverse events were seen in three percent of patients.⁴ Ninety-nine percent of infusion-related reactions occurred with the first infusions and rarely impacted the ability to continue with subsequent treatments (1.1 percent led to treatment discontinuation).⁴

"This marketing authorisation addresses a high unmet need by bringing a new treatment option to this patient population and their healthcare professionals for the first time in Europe. It is an important step towards our goal to deliver innovative therapies that will transform the trajectory of lung cancer," commented Peter Lebowitz, M.D., Ph.D., Global Therapeutic Area Head, Oncology, Janssen Research & Development, LLC.

Conditional marketing authorisation is the approval of a medicine that addresses unmet medical needs of patients based on less comprehensive data than normally required, where the benefit of immediate availability of the medicine outweighs the risk, and the applicant is able to provide comprehensive clinical data in the future.⁷ This CMA follows other recent approvals for amivantamab, including the U.S. Food and Drug Administration (FDA), who approved the treatment in May 2021 for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy.⁸ Additional regulatory applications have been submitted and are being reviewed by other regulatory bodies worldwide.

"We are committed to changing the face of cancer care," said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, Johnson & Johnson. "At Janssen, we’re striving to transform long-term patient outcomes and improve quality of life with the right treatment, for the right patient, at the right time."

† Dr Passaro has previously provided paid consultancy services for Janssen in relation to research and advisory boards. He has not been compensated for any media work.

‡ Results reported in the SmPC are from 114 patients with a median follow up of 12.5 months.⁴ Results reported in Park et al are from 81 patients and a median follow up of 9.7 months.⁶ Not all efficacy endpoints were reported in the SmPC.^4,6

About Amivantamab

Amivantamab is a fully-human EGFR-MET bispecific antibody with immune cell-directing activity that targets tumours with activating and resistance EGFR mutations and MET mutations and amplifications, approved for patients with advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations after failure of platinum-based therapy.^1,9,10,11,12 Amivantamab is being studied in multiple clinical trials, including:¹³

• the Phase 1/1b, CHRYSALIS-2 (NCT04077463) study assessing thecombination of amivantamab and lazertinib in patients who have progressedafter treatment with osimertinib and chemotherapy, as well as lazertinibas a monotherapy¹⁴
• as first-line therapy in thePhase 3 MARIPOSA (NCT04487080) study assessing amivantamabin combination with lazertinib, a novel third-generation EGFR tyrosinekinase inhibitor (TKI), against osimertinib and against lazertinib alonein untreated advanced EGFR-mutated NSCLC¹⁵
• the Phase 3 MARIPOSA-2 (NCT04988295) study assessing the efficacyof lazertinib, amivantamab and carboplatin-pemetrexed vs. withcarboplatin-pemetrexed in participants with locally advanced or metastaticEGFR Exon 19del or Exon 21 L858R substitution NSCLC after osimertinibfailure¹⁶
• the Phase 3 PAPILLON (NCT04538664)study assessing amivantamab incombination with carboplatin-pemetrexed vs carboplatin-pemetrexed forpatients with advanced or metastatic EGFR-mutated NSCLC with exon 20insertion mutations¹⁷
• the Phase 1 PALOMA (NCT04606381) study assessing thefeasibility of subcutaneous (SC) administration of amivantamab based onsafety and pharmacokinetics and to determine a dose, dose regimen andformulation for amivantamab SC delivery with the aim to find effectivesolutions that positively impact patient management.¹⁸

About the CHRYSALIS Study

CHRYSALIS (NCT02609776) is an open-label, multicentre, first-in-human Phase 1 study to evaluate the safety, pharmacokinetics and preliminary efficacy of amivantamab as a monotherapy, in combinations with lazertinib and in combination with platinum-based chemotherapy, in patients with advanced NSCLC with various EGFR mutations.³ In the study, investigators assessed efficacy using overall response rate per Response Evaluation Criteria in Solid Tumours Version 1.1* (RECIST v1.1), clinical benefit rate, median duration of response and median progression-free survival, as well as the safety profile of amivantamab.^3,19

The study will enrol 780 patients with advanced NSCLC.³ The study consists of two parts: the first consists of amivantamab monotherapy and combination dose escalations, and the second consists of amivantamab monotherapy and combination dose expansions.³

The first cohort of participants received intravenous infusions of amivantamab as monotherapy.³

*RECIST (version 1.1) refers to Response Evaluation Criteria in Solid Tumours, which is a standard way to measure how well solid tumours respond to treatment and is based on whether tumours shrink, stay the same or get bigger.³

About Non-Small Cell Lung Cancer (NSCLC)

In Europe, it is estimated that 477,534 patients were diagnosed with lung cancer in 2020, with around 85 percent diagnosed with NSCLC.^20,21 Lung cancer is Europe’s biggest cancer killer, with more deaths than breast cancer and prostate cancer combined.²⁰

The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma and large cell carcinoma.²¹ Among the most common driver mutations in NSCLC are alterations in EGFR, which is a receptor tyrosine kinase supporting cell growth and division.²² EGFR mutations are present in 16 to 19 percent of Caucasian patients with NSCLC and present in 37 to 41 percent of Asian patients who have NSCLC adenocarcinoma.²³ The five-year survival rate for all people with metastatic NSCLC and EGFR mutations who are treated with EGFR TKIs is less than 20 percent.²⁴ Patients with EGFR exon 20 insertion mutations have a real-world five-year overall survival (OS) of 8 percent in the frontline setting, which is worse than patients with EGFR exon 19 deletions or L858R mutations, who have a real-world five-year OS of 19 percent.²⁵

About the Janssen Pharmaceutical Companies of Johnson & Johnson

At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology and Pulmonary Hypertension.

Learn more at www.janssen.com/emea/. Follow us at www.twitter.com/JanssenEMEA for our latest news. Janssen Research & Development, LLC; Janssen-Cilag, S.A. and Janssen Biotech, Inc. are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Contacts

Media:
Noah Reymond
+31 621 38 5718
NReymond@its.jnj.com

Sarah Jones
+44 7917 849 211
SJones39@its.jnj.com

Investor Relations:
Jessica Moore
+41 79 395 4823
Jmoore29@its.jnj.com

Source: Janssen

תוכן הודעה זו בשפת המקור, הוא הגרסה הרשמית והמהימנה היחידה של מסמך זה. התרגומים הם למטרות נוחות בלבד ויש להצליבם עם המסמך בשפת המקור, שהוא הגרסה היחידה של טקסט זה שהוא בעל תוקף משפטי.

*** הידיעה מופצת בעולם על ידי חברת התקשורת הבינלאומית Business Wire